Skip to content
Lower risk Drug recall · FDA · Published October 3, 2018

InvaGen Amlodipine Tablets Recall: Subpotent Drug Risk

InvaGen Pharmaceuticals recalls 10 mg Amlodipine Besylate tablets due to subpotent drug quality. This means the medication may not be as effective as labeled, potentially requiring higher doses for treatment.

🇺🇸 FDA recall #D-0012-2019DrugInvaGen Pharmaceuticals ›
Take action

Contact the company

Recalling firmInvaGen Pharmaceuticals, Inc.7 Oser Ave · Hauppauge, NY 11788-3811
✎ GovInfoNow plain-language explainer

InvaGen Pharmaceuticals is recalling 10 mg Amlodipine Besylate tablets that may not contain the full amount of active ingredient. This could lead to the medication being less effective than intended, requiring higher doses for the same treatment effect. Read more at govinfonow.com/recall/39538-invagen-amlodipine-tablets-recall-subpotent-drug-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/39538-invagen-amlodipine-tablets-recall-subpotent-drug-risk · Updated October 6, 2026 · FDA enforcement record: FDA #D-0012-2019

Cite this page

“InvaGen Amlodipine Tablets Recall: Subpotent Drug Risk.” GovInfoNow, updated October 6, 2026. https://govinfonow.com/recall/39538-invagen-amlodipine-tablets-recall-subpotent-drug-risk. Based on FDA recall #D-0012-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0012-2019%22&limit=1).

InvaGen Pharmaceuticals, Inc. voluntarily recalled Amlodipine Besylate USP 10 mg Tablets on Oct. 3, 2018, after the FDA announced one lot was subpotent. The Food and Drug Administration issued recall number D-0012-2019 for the Class III product distributed nationwide.

How to tell if you have it

  • Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles
  • UPC 369097128159
  • NDC 69097-128-15
  • Lot #: GG80218
  • Exp. 12/2019

The hazard

The FDA stated that one lot of the product does not meet the specification for the Assay test under 3-month long-term stability conditions, resulting in a subpotent drug. The record provides no information regarding incidents or injuries.

Context

GovInfoNow's records show InvaGen Pharmaceuticals, Inc. has had seven other recalls since March 5, 2018. Other recent recalls of similar products include Ascend Laboratories recalls Amlodipine/Olmesartan tablets with low drug content (July 8, 2026), Unichem busPIRone 5mg Tablets Recall: Subpotent Drug Risk (April 13, 2026), and Ascend Laboratories recalls 5mg/40mg blood pressure tablets due to low drug content (May 5, 2026).

How to tell if you have this one

Check for the lot number GG80218 on the bottle label. The product is a 1000-count bottle of 10 mg Amlodipine Besylate tablets, manufactured by Cipla Ltd. in India, with an expiration date of December 2019.

  • Brand
    InvaGen Pharmaceuticals
  • Product
    Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the lot number GG80218 on the bottle label to confirm if the product is affected.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide with the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.8 years after the firm started it.

1. Firm started the recall: Oct 3, 201812. FDA classified it Class III: Oct 11, 201823. Published in FDA’s Enforcement Report: Oct 17, 201834. FDA terminated the recall: Jul 13, 2021420182021
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this medication safe to use?

The recall indicates a potential issue with the medication's effectiveness, but it is not unsafe in terms of causing injury. The product may require higher doses for the same effect.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0012-2019 (October 3, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0012-2019 to see it in context.
  • Plain-language summary written by qwen3:4b on October 6, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA